Subjects
Thirty-four newly admitted acute schizophrenic patients were studied: they included first admissions and others undergoing acute exacerbations with a history of previous acute schizophrenic episodes. None of these patients had received tranquillizing medication for at least one month prior to admission to hospital, or electroconvulsive therapy for at least two months. They ranged in age from seventeen to fifty-four years with a mean age of thirty-four. Some preliminary. findings with the first twenty subjects in this series have already been published (4). coefficient of variation (CV) than the other fifty-five patients who were receiving a variety of drugs. The procedure described here permitted a more detailed analysis of the effects of two antipsychotic agents (quite different in chemical structure) upon the integrated EEG measures in a more systematic comparative design of shortterm drug effects. It also permitted a comparison of effects, both clinical and EEG, over a time period (seven days) similar to that in which the clinician might ordinarily decide whether his patient was showing satisfactory response, leading him to continue a particular antipsychotic compound or switch to another.
Method
Each patient spent one week on chlorprothixene or haloperidol and one week on placebo in a randomized double-blind cross-over design. The average doses administered per day were 251 mg. of chlorprothixene and 9 mg. of haloperidol on a free dosage range according to severity of symptoms and apparent response. ( Haloperidolt, a butyrophenone derivative, has been demonstrated to be effective in the treatment of agitated states and also in schizophrenia (2) . In this study, the effects of this drug were compared with those of chlorprothixene t t (one of the thioxanthene derivatives of the phenothiazine group of tranquillizers) in terms of clinical and EEG changes in a series of acute schizophrenic patients.
Pratt et al. (7) described a study in which the clinical effects of haloperidol were compared with those of chlorpromazine in a sample of fifty-eight acute schizophrenics. They found that, although there were no significant differences between their two drug groups on a variety of psychological tests and rating scales, the haloperidol group showed greater improvement. Entwhistle et al. (1) reported basically the. same results with manic patients, and stated that haloperidol had more rapid effects and produced greater tranquillization than did chlorpromazine.
EEG mean integrated amplitude (MIA) and its variability over time, the coefficient of variation (CV score), have been shown to be sensitive to clinical symptomatic change induced by antipsychotic agents of a wide variety in chronic schizophrenic patients (8) . In a study carried out by two of the present authors (5) it was observed that five unmedicated acute schizophrenics in the subject group had a higher mean 100-400 mg., and of haloperidol from 5-16 mg./day). Tablets containing placebo or either of the two drugs were all visually identical.
EEG activity was electronically integrated before the subject was randomly assigned to either a drug or a placebo treatment and again at the end of the first and the second week on the study by an EEG method described more fully elsewhere (5) 
Results
Scores for a number of IMPS syndromes showed change over the three ratings. Wilcoxon's sign-rank test indicated that there were significant changes over the week of active drug treatment for both drug groups (see Table I ). The same test did not reveal any significant rating changes over the 'placebo week' for either group. In terms of global rating, significantly more patients showed clinical improvement over the drug week' as compared to the 'placebo week' (for chlorprothixene, X~= 5.15 and foi'" haloperidol, X' = 6.84, p for both <.05). The Mann-Whitney U Test failed to demonstrate significant differences between clinical changes ( as measured by IMPS syndrome score changes) for the two drugs although, as can be seen from Table I , the haloperidol group showed significant change on a greater number of IMPS syndromes.
EEGs showed a mean increase in both MIA and CV from baseline to drug recordings over the total series of patients, but these differences by analysis of variance were not significant. Change on only one of the IMPS syndromes correlated significantly with EEG change: there was a relationship between changes on conceptual disorganization (CNP) and CV change in the chIorprothixene group (r, = -.46, P <.05). This indicated that an increase in CV was. associated with improvement in conceptual organization. This relationship was not found in the haloperidol group.
In the preliminary report dealing with these problems (4) an interaction between drug effect and field dependence was observed. Field-independent subjects in the chlorpromazine-chIorprothixene group showed a CV increase while field-dependent subjects showed a decrease; with haloperidol the situation was opposite. Although there was still a tendency for field-independent subjects to show a CV increase with chlorprothixene and a decrease for haloperidol (Table II) this relationship was not significant with the increased subject group. However, there was a significant positive correlation between CV change and RFT scores across both drug groups (r, = .37, p <.05). This means that field-dependent subjects tended to have greater increases Haloperidol
6~-and smaller decreases in EEG signal variability (CV Scores) with tranquillizer than do field-independent subjects. In the haloperidol group RFT scores were also significantly correlated with MIA change (r, = -.48, P <.05): MIA tended to decrease with drugs in field-independent patients and increase in field-dependent ones. The two drug groups were not significantly different in their distribution of RFT Scores.
Discmwion
Clinical .improvement over a seven-day trial period followed the administration of either chlorprothixene or haloperidol, but although haloperidol appeared to be slightly superior to chlorprothixene (a larger number of IMPS syndromes showed significant change) direct comparison of the two drugs did not reveal significant differences in their effects on the symptom factors.
It also appeared that the two drugs although rather different in chemical structure did not produce clearly different effects on those EEG measures which have been shown to relate to certain features of schizophrenic illness (5, 6, 8) . The correlations of the drug-induced changes on the integrated EEG measures with the field-dependency scores, within the two drug groups, indicated again the apparent necessity to account for individual differences in perceptual field-dependency when attempts are made to study the psychopharmacological or neurophysiological responses of schizophrenics (6).
The effects on both EEG and on symptom ratings might, of course, have discriminated more clearly between the two drugs if each had been given for longer than seven days. The present data were interpreted only in terms of this brief period of clinical observation but statistically significant improvement in double-blind rated clinical status did occur in both drug treatment groups.
